Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study.

Saved in:

Bibliographic Details
Title:	Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study.
Authors:	Hackam, Daniel G, Thiruchelvam, Deva, Redelmeier, Donald A
Source:	Lancet. 8/19/2006, Vol. 368 Issue 9536, p659-665. 7p. 2 Charts, 2 Graphs.
Subjects:	ACE inhibitors, Aortic aneurysm treatment, Clinical drug trials, Aneurysm treatment, Medical research, Rupture (Book), Abdominal aorta, Antihypertensive agents, Diseases
Abstract:	Summary Background Angiotensin-converting enzyme (ACE) inhibitors prevent the expansion and rupture of aortic aneurysms in animals. We investigated the association between ACE inhibitors and rupture in patients with abdominal aortic aneurysms. Methods We did a population-based case-control study of linked administrative databases in Ontario, Canada. The sample included consecutive patients older than 65 (n=15 326) admitted to hospital with a primary diagnosis of ruptured or intact abdominal aortic aneurysm between April 1, 1992, and April 1, 2002. Findings Patients who received ACE inhibitors before admission were significantly less likely to present with ruptured aneurysm (odds ratio [OR] 0·82, 95% CI 0·74-0·90) than those who did not receive ACE inhibitors. Adjustment for demographic characteristics, risk factors for rupture, comorbidities, contraindications to ACE inhibitors, measures of health-care use, and aneurysm screening yielded similar results (0·83, 0·73-0·95). Consistent findings were noted in subgroups at high risk of rupture, including patients older than 75 years and those with a history of hypertension. Conversely, such protective associations were not observed for β blockers (1·02, 0·89-1·17), calcium channel blockers (1·01, 0·89-1·14), α blockers (1·15, 0·86-1·54), angiotensin receptor blockers (1·24, 0·71-2·18), or thiazide diuretics (0·91, 0·78-1·07). Interpretation ACE inhibitors are associated with a reduced risk of ruptured abdominal aortic aneurysm, unlike other antihypertensive agents. Randomised trials of ACE inhibitors for prevention of aortic rupture might be warranted. [ABSTRACT FROM AUTHOR]
	Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	Psychology and Behavioral Sciences Collection

Description
Abstract:	Summary Background Angiotensin-converting enzyme (ACE) inhibitors prevent the expansion and rupture of aortic aneurysms in animals. We investigated the association between ACE inhibitors and rupture in patients with abdominal aortic aneurysms. Methods We did a population-based case-control study of linked administrative databases in Ontario, Canada. The sample included consecutive patients older than 65 (n=15 326) admitted to hospital with a primary diagnosis of ruptured or intact abdominal aortic aneurysm between April 1, 1992, and April 1, 2002. Findings Patients who received ACE inhibitors before admission were significantly less likely to present with ruptured aneurysm (odds ratio [OR] 0·82, 95% CI 0·74-0·90) than those who did not receive ACE inhibitors. Adjustment for demographic characteristics, risk factors for rupture, comorbidities, contraindications to ACE inhibitors, measures of health-care use, and aneurysm screening yielded similar results (0·83, 0·73-0·95). Consistent findings were noted in subgroups at high risk of rupture, including patients older than 75 years and those with a history of hypertension. Conversely, such protective associations were not observed for β blockers (1·02, 0·89-1·17), calcium channel blockers (1·01, 0·89-1·14), α blockers (1·15, 0·86-1·54), angiotensin receptor blockers (1·24, 0·71-2·18), or thiazide diuretics (0·91, 0·78-1·07). Interpretation ACE inhibitors are associated with a reduced risk of ruptured abdominal aortic aneurysm, unlike other antihypertensive agents. Randomised trials of ACE inhibitors for prevention of aortic rupture might be warranted. [ABSTRACT FROM AUTHOR]
ISSN:	01406736
DOI:	10.1016/S0140-6736(06)69250-7